This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

GlaxoSmithKline to appeal judgment in Alabama Medicaid pricing suit

Issued: Philadelphia, PA – July 1, 2008

GlaxoSmithKline (NYSE:  GSK) announced today that it intends to appeal a Montgomery County Circuit Court jury verdict against GSK regarding the process for reporting of prices for drugs reimbursed by Medicaid in the State of Alabama. 

The company was among 73 pharmaceutical manufacturers named in a lawsuit filed by the Alabama Attorney General in January 2005.  Both GSK and Novartis argued before the Court in this round of litigation. 

“We have said from the beginning that GSK reported true and accurate prices to the state of Alabama,” said Chilton Varner, an attorney with King & Spalding of Atlanta who represented GSK. “We believe the evidence shows the State made informed choices about how and how much to pay Alabama pharmacists. Evidence also shows that, although the State now says it was not being fairly treated, the State has not changed the rules since it filed the lawsuit more than three years ago.” 

The Alabama jury found Novartis liable for $33.2 million in compensatory damages and no punitive damages, along with $80.9 million compensatory damages and no punitive damages against GSK.  In February, a separate jury imposed similar charges against AstraZeneca, awarding the State $40 million in compensatory damages and $175 million in punitive damages. A state judge recently reduced that amount to $120 million, because Alabama limits punitive damages to three times compensatory damages.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For company information, visit GlaxoSmithKline on the World Wide Web at www.gsk.com.

Inquiries

US Media inquiries:	Nancy Pekarek	(215) 751 7709
	Mary Anne Rhyne	(919) 483 2839
	Sarah Alspach	(215) 751 7709
UK Media inquiries:	Phil Thomson	(020) 8047 5502
	Alice Hunt	(020) 8047 5502
	Gwenan White	(020) 8047 5502
US Analyst/ Investor inquiries:	Frank Murdolo	(215) 751 7002
	Tom Curry	(215) 751 5419
European Analyst/Investor inquiries:	David Mawdsley	(020) 8047 5564
	Sally Ferguson Gary Davies	(020) 8047 5543 (020) 8047 5503